CoChat

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Increases in serum prolactin concentrations after administration of risperidone have been attributed, by some, to the availability of paliperidone in plasma. This double-blind, randomized, parallel-group study in patients with schizophrenia compared serum prolactin concentrations following the administration of paliperidone extended-release and risperidone immediate-release tablets. At steady state, the doses administered resulted in a similar exposure to paliperidone and the pharmacologically active fraction of risperidone (i.e. risperidone + paliperidone), respectively. Eligible patients were randomized to either paliperidone extended-release 12 mg on days 1—6 or risperidone immediate-release 2 mg on day 1 and 4 mg on days 2—6. Mean serum prolactin concentrations increased on day 1 (C max : 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively). On day 6, serum prolactin concentration—time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC 0—24 h : 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively). These results indicate that paliperidone extended-release 12 mg and risperidone immediate-release 4 mg, administered over a period of 6 days, lead to similar elevations in serum prolactin concentrations.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881109106914

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. Cleton A., 2007, Clin Pharm Rev, 81, S62
  2. Heykants J., 1994, J Clin Psychiatry, 55, 13
  3. Invega Prescribing Information, 2006, Janssen Pharmaceuticals

Cited by

See all 49

Metadata

Authors
Berwaerts, J., Cleton, A., Rossenu, S., Talluri, K., Remmerie, B., Janssens, L., Boom, S., Kramer, M., & Eerdekens, M.
Affiliations
  • Johnson & Johnson (United States) (US)
  • Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium
  • Janssen Research & Development (United States) (US)
  • Johnson & Johnson Pharmaceutical Research and Development Early Development, San Diego, CA, USA
Corresponding author
Berwaerts, Joris
Venue
Journal of Psychopharmacology
Published
2009-10-13
Volume
24
Issue
7
Pages
1011-1018
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W1965085115
Cited by
49
References
25
Citations by year
2026: 2 · 2025: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 9 · 2012: 6
FWCI
2.89
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
serum prolactin, paliperidone extended-release, risperidone, schizophrenia, antipsychotic adverse effects, drug exposure, pharmacokinetics, prolactin elevation, atypical antipsychotics
MeSH terms
Paliperidone Palmitate, Adolescent, Adult, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypotension, Orthostatic, Isoxazoles, Male, Middle Aged, Prolactin, Psychiatric Status Rating Scales, Pyrimidines, Schizophrenia, Antipsychotic Agents, Risperidone, Area Under Curve, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.